Tonix Pharmaceuticals Holding Corp. - TNXP STOCK NEWS

Tonix Pharmaceuticals (Nasdaq: TNXP) announced a live webinar on September 24, 2020, at 10:00 a.m. ET, focusing on antibody versus T cell immune responses and vaccine development challenges. The event features experts from IAVI, Merck, and Tonix, moderated by Clive Cookson of the Financial Times. Participants include Swati Gupta (IAVI), Seth Lederman (CEO, Tonix), and Gokul Swaminathan (Merck). An archived recording will be available on Tonix's investor website. Tonix's lead vaccine candidate is TNX-1800, targeting COVID-19.

Tonix Pharmaceuticals (NASDAQ: TNXP) announced the enrollment of its first patient in the COV-LOGIC study (TNX-C001), aimed at understanding immune responses to SARS-CoV-2 in recovered or asymptomatic individuals. This research will aid in developing the TNX-1800 vaccine, designed to elicit T cell responses. The study will analyze antibody titers and T-cell responses through blood and swab samples, contributing to the broader collaboration with Southern Research. Tonix aims for a well-tolerated, effective vaccine with strong immunity against COVID-19.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced its second-quarter financial results as of June 30, 2020, highlighting progress in developing its COVID-19 vaccine candidate, TNX-1800. The company expects preclinical data for TNX-1800 in Q4 2020 and has completed the enrollment for the Phase 3 RELIEF trial of TNX-102 SL for fibromyalgia ahead of schedule. Financially, Tonix reported a net loss of $14.2 million ($0.23 per share) compared to $5.8 million ($9.42 per share) in Q2 2019. The company holds $55 million in cash and raised approximately $9.6 million through a recent stock offering.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced FDA clearance for its IND application to initiate a Phase 2 study of TNX-102 SL for treating alcohol use disorder (AUD). This milestone positions TNX-102 SL for potential FDA approval under the 505(b)(2) pathway. The company highlights the significance of improving sleep quality, which may enhance recovery rates for the estimated 36 million adults in the U.S. affected by AUD. Tonix continues to develop a robust pipeline of CNS and immunology products, including vaccines for infectious diseases and biologics targeting various conditions.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it has regained compliance with NASDAQ's minimum bid price requirement, following a letter received on August 3, 2020. The company’s shares closed above $1.00 for ten consecutive business days, satisfying NASDAQ Listing Rule 5450(a)(1). This is significant for the company as it ensures continued listing on the NASDAQ Global Market. Tonix focuses on developing small molecules and biologics for central nervous system and immunology indications, including COVID-19 vaccine candidates and treatments for fibromyalgia.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced preclinical results for TNX-1900, an intranasal oxytocin solution, to be presented at the American Academy of Neurology's Sports Concussion Conference on July 31 and August 1, 2020. The study, sponsored by Trigemina, reveals TNX-1900's potential to relieve pain and depressive behavior in a rodent model of mild traumatic brain injury. Tonix acquired Trigemina's assets in June, including valuable data for TNX-1900. The company is focused on developing solutions for CNS and immunology conditions, with several clinical-stage products in its pipeline.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has rescheduled its Special Meeting of Stockholders to August 28, 2020, moving it from June 26, 2020. The record date for stockholders eligible to vote is now July 15, 2020. The meeting will cover proposals previously mentioned in the proxy statement, with no new proposals introduced. Stockholders are encouraged to register online to attend the meeting. Tonix is developing vaccines and CNS therapies, including TNX-1800 for COVID-19, with data expected from animal studies in Q4 2020.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has successfully closed a registered direct offering, generating approximately $10.5 million before fees. The company issued 20,940,000 shares at $0.50 per share, raising its total outstanding shares to 125,743,906. A.G.P./Alliance Global Partners acted as the placement agent. This offering was made under an effective shelf registration statement with the SEC. Tonix focuses on developing therapies for CNS and immunology, with its lead candidates addressing COVID-19 and fibromyalgia.

Tonix Pharmaceuticals Holdings Corp. (NASDAQ: TNXP) has announced a securities purchase agreement with institutional investors for the sale of 20,940,000 shares at $0.50 per share, totaling approximately $10.5 million in gross proceeds. The registered direct offering is set to close on or about July 15, 2020. A.G.P./Alliance Global Partners is acting as the sole placement agent. Tonix is focused on developing treatments for CNS disorders and immunology, including vaccines for COVID-19 and smallpox, with upcoming data from various clinical trials expected in late 2020.